No abstract available.
Peripheral Arterial Disease*

No abstract available.
Adult* ; Humans ; Prevalence*

No abstract available.
Metabolism*

No abstract available.
Thyroiditis, Autoimmune*

No abstract available.
Diabetes Mellitus, Type 2*

No abstract available.

A study was conducted on 2,210 officials in Jeonbug Province to check out their physical growth, development and nutritional state during the period June 1st 1975 to August 31, 1975. As the results of this study, the following conclusions were reached: 1. Physical measurement. a. Body height: The mean body height of male was 166.8+/-4.6 cm and that of female was 156.3+/-4.9 cm. The highest value of mean body height was 167.1+/-3.9cm, showing by male of administrative job. The lowest value of that was 165.7+/-5.2cm, showing by the male functional job, while the difference of body height was not significant in female. b. Body weight: The mean body weight of male was 61.5+/-4.6kg and that of female was 51.2+/-3.9kg. The administrative job heavier than functional job of male by type of job, while that of female of functional job heavier than functional job of male by type of job, while that of female of functional job heavier than administrative job. c. Chest-girth: The mean body chest-girth of male was 90.8+/-3.2cm and that of female was 83.6+/-3.6cm. 2. Physical growth and developmental state. a. The relative body weight was normal in male except the young man under 25 years, while that of female was under the level of standard. b. The relative chest-girth was showed standard values by all age group of officials. c. The Rogrer and Kaup indices were showed standard values except under 19 years officials and 30 to 34 years female officials. 3. Vervaeck index for nutritional status was appeared normal in male but under the values of standard in female.
Body Height ; Body Weight ; Female ; Growth and Development ; Humans ; Jeollabuk-do* ; Male ; Nutritional Status

No abstract available.
Diabetes Mellitus, Type 2* ; Obesity* ; PPAR gamma*

BACKGROUND: Tego-51(R), one of the amphoteric surfactants, has been considered as an effective disinfectant having both bactericidal and fungicidal effect. The author evaluated inactivation effect of Tego-51(R) on viruses causing disease in humans. METHODS: Influenza virus B, respiratory syncytial virus (RSV), herpes simplex virus 1 (HSV-1), adenovirus and echovirus 30 were exposed to diluted Tego-51(R) solution (1% and 0.1%) for 5, 10 and 30 minutes respectively and were inoculated onto the following cells: Influenza virus B, MDCK; RSV, HEp-2; HSV-1, HEp-2; adenovirus, Vero; and echovirus 30, RD. After incubation for 5 to 6 days, viral infection was identified with indirect immunofluorescent methods. RESULTS: Influenza virus B, RSV and HSV-1 which are enveloped viruses were inactivated after exposure of the viruses to Tego-51(R) for 5 minutes. Non-enveloped adenovirus and echovirus 30 were not inactivated after exposure for 30 minutes. CONCLUSIONS: Tego-51(R) appears to be effective in inactivation of enveloped viruses at concentrations used for disinfection of pathogenic bacteria and fungi.
Adenoviridae ; Bacteria ; Disinfection ; Enterovirus B, Human ; Fungi ; Herpesvirus 1, Human ; Humans ; Orthomyxoviridae ; Respiratory Syncytial Viruses ; Surface-Active Agents ; Virus Inactivation*

Newer antidepressants are commonly used in clinical practice to treat psychiatric disorder and psychosomatic disorder including chronic pain syndrome, fibromyalgia, headache. However there are many unexpected adverse effects of these drugs such as nausea and vomiting, weight gain, sexual dysfunction. These are 3 most well-recognized common adverse effects of newer antidepressant and are most common causes of treatment failure. I reviewed mechanisms, epidemiology, and pharmacological management of these adverse effects of newer antidepressants. In this paper, newer antidepressants include selective serotonin reuptake inhibitor(fluoxetine, fluvoxamine, citalopram, escitalopram, sertraline, paroxetine), serotonin norepinephrine reuptake inhibitor(venlafaxine, duloxetine), norepinephrine and dopamine reuptake inhibitor(bupropion), noradrenergic and specific serotonergic antidepressant(mirtazapine), and reversible inhibitor of MAO-A(moclobemide). I suggest that psychiatrists and clinicians in the psychosomatic field should know mechanisms, epidemiology, and management of these common and well-recognized adverse effects of newer antidepressants. Therefore it will be helpful to recognize easily and treat well for patients with psychiatric disorder and psychosomatic disorder using newer antidepressants.
Antidepressive Agents ; Chronic Pain ; Citalopram ; Dopamine ; Epidemiology* ; Fibromyalgia ; Fluvoxamine ; Headache ; Humans ; Nausea* ; Norepinephrine ; Psychiatry ; Psychophysiologic Disorders ; Serotonin ; Sertraline ; Treatment Failure ; Vomiting* ; Weight Gain*